Phase III data of Nexavar for Thyroid Cancer published in The Lancet - Bayer HealthCare/Onyx Pharma

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals announced that The Lancet published online results from the Phase III DECISION trial which demonstrated that Nexavar (sorafenib) tablets significantly extended the time patients with locally recurrent or metastatic, progressive, differentiated Thyroid Carcinoma that is refractory to radioactive iodine treatment lived without their disease worsening. Based on these data, Nexavar was approved by the FDA in November 2013 for patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment. These patients previously had limited approved treatment options. See: "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial." Dr Marcia S Brose et al. The Lancet, Early Online Publication, 24 April 2014 doi:10.1016/S0140-6736(14)60421-9